Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 44, showing 5 Applications out of 218 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/25/05/12   SAFIRE
    A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR)
 
View

107.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
View

108.

ECCT/25/04/04   LIMIT
    A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT)   
Principal Investigator(s)
1. Anthony KIBUKA Gikonyo
Site(s) in Kenya
The Karen Hospital
 
View

109.

ECCT/25/05/05   Hibiscus 2 - Site 252
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county)
 
View

110.

ECCT/25/05/03   Hibiscus 2 - Site 253
    A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease.   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Site 253 - International Cancer Institute (Uasin Gishu county)
 
View